Focused On-demand Library for TBC1 domain family member 4

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
O60343

UPID:
TBCD4_HUMAN

ALTERNATIVE NAMES:
Akt substrate of 160 kDa

ALTERNATIVE UPACC:
O60343; A7E2X8; B4DU25; B4E235; B6ETN8; B6ETN9; Q5W0B9; Q68D14

BACKGROUND:
The protein TBC1 domain family member 4, alternatively known as Akt substrate of 160 kDa, is instrumental in regulating glucose homeostasis through its action on various RAB GTPases and facilitating GLUT4 translocation. This function is vital for maintaining normal glucose levels in the body.

THERAPEUTIC SIGNIFICANCE:
Given its pivotal role in the pathogenesis of Type 2 diabetes mellitus 5, understanding the role of TBC1 domain family member 4 could open doors to potential therapeutic strategies. Developing interventions that modulate this protein's activity offers a promising avenue for diabetes treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1032 of 8789